Early signs of ovarian cancer are symptoms many women experience, sometimes making it go undetectable until late stages. As a result, only 16% of ovarian cancer is diagnosed in early stages, and ovarian cancer is the deadliest gynecologic cancer, with a five-year survival rate of less than 30% when detected in late stages.
Detecting ovarian cancer in Black women presents physicians with an even greater challenge. CA125 is a common ovarian cancer risk assessment test in all women, despite its limited sensitivity and specificity. However, CA125 is expressed at lower levels in Black women and therefore is even less accurate in assessing risk.
Aspira Women’s Health is evolving and accelerating risk detection, directly addressing the current disparities that exist in ovarian cancer detection.
Learn more here.